CD8A and neoplasm: Since CD226 agonist antibody-mediated activation of CD226 augments the effect of TIGIT blockade on CD8+ T cell responses, PKC can potentially represent a pharmacological target to stimulate intra-tumor CD8+ T cells to promote CD226 migration to the lipid raft to facilitate activation by phosphorylation at Tyr322.